alpidem
Sign in to saveAlpidem, sold under the brand name Ananxyl, is a nonbenzodiazepine anxiolytic medication which was briefly used to treat anxiety disorders but is no longer marketed. It was previously marketed in France, but was discontinued due to liver toxicity. Alpidem is taken by mouth.
Key facts
- Drug.verifiedrevid
- 443275474
- Drug.image
- Alpidem.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 222px
- Drug.tradename
- Ananxyl
- Drug.routes_of_administration
- Oral administration
- Drug.class
- Nonbenzodiazepine; GABAA receptor positive allosteric modulator; Anxiolytic
- Drug.ATC_prefix
- None
- Drug.legal_status
- Rx-only
- Drug.bioavailability
- 32–35% (estimated)
- Drug.protein_bound
- 99.4%
- Drug.metabolism
- Extensive (hydroxylation, dealkylation, conjugation)
- Drug.metabolites
- Many (some active)
- Drug.onset
- 1.0–2.5 hours (Cmax)
- Drug.elimination_half life
- Young adults: 19 hours (7–44 hours)Elderly: 22.6 ± 2.3 hoursChildren: 11.4 ± 1.9 hours
- Drug.excretion
- Mainly feces
- Drug.CAS_number
- 82626-01-5
- Drug.PubChem
- 54897
via Wikipedia infobox
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 403.122
Show 4 more facts
- chemical formula
- C₂₁H₂₃Cl₂N₃O
- canonical SMILES
- CCCN(CCC)C(=O)CC1=C(N=C2N1C=C(C=C2)Cl)C3=CC=C(C=C3)Cl
- subject has role
- anxiolytic
- Commons category
- Alpidem
Sources (2)
via Wikidata · CC0
~15 min read
Encyclopedic overview
21 sectionsContents
- Medical uses
- Available forms
- Side effects
- Overdose
- Interactions
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- Absorption
- Distribution
- Metabolism
- Elimination
- Chemistry
- History
- Society and culture
- Names
- Availability
- See also
- References
- Further reading
- External links
Alpidem, sold under the brand name Ananxyl, is a nonbenzodiazepine anxiolytic medication which was briefly used to treat anxiety disorders but is no longer marketed. It was previously marketed in France, but was discontinued due to liver toxicity. Alpidem is taken by mouth.
Side effects of alpidem include sedation, fatigue, dizziness, and headache, among others. It has much less to no impact on cognition, memory, and psychomotor function relative to benzodiazepines. Similarly, no rebound anxiety or withdrawal symptoms have been observed with alpidem. Rarely, alpidem can cause serious liver toxicity, including liver failure and death. Alpidem is a nonbenzodiazepine of the imidazopyridine family, structurally related to the Z-drug zolpidem, and acts as a GABAA receptor positive allosteric modulator of the benzodiazepine site of the receptor complex. In contrast to zolpidem however, alpidem has anxiolytic effects rather than sedative or hypnotic effects at normal therapeutic doses.
Excerpted from Wikipedia’s “alpidem” article, available under the CC BY-SA 4.0 licence.
Available in 9 languages
via Wikidata sitelinks · CC0